Changchun BCHT Biotechnology Co. (SHA:688276)
China · Delayed Price · Currency is CNY 18.13
-0.01 (-0.06%)
Apr 29, 2026, 3:00 PM CST
SHA:688276 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 590.13 | 605.07 | 1,229 | 1,825 | 1,071 | 1,201 |
Other Revenue | - | - | - | 0.14 | 0.05 | 0.75 |
| 590.13 | 605.07 | 1,229 | 1,825 | 1,071 | 1,202 | |
Revenue Growth (YoY) | -47.36% | -50.77% | -32.64% | 70.30% | -10.86% | -16.61% |
Cost of Revenue | 164.89 | 160.74 | 206.06 | 210.35 | 181.93 | 228.56 |
Gross Profit | 425.24 | 444.34 | 1,023 | 1,614 | 889.52 | 973.47 |
Selling, General & Admin | 482.56 | 500.05 | 582.83 | 800.93 | 552.73 | 555.93 |
Research & Development | 172.59 | 177.1 | 156.14 | 198.07 | 133.53 | 156.76 |
Other Operating Expenses | -17.08 | -16.17 | 9.83 | 13.04 | 9.7 | 10.58 |
Operating Expenses | 638.07 | 660.98 | 772.28 | 1,072 | 729.59 | 734.04 |
Operating Income | -212.83 | -216.64 | 250.74 | 541.96 | 159.93 | 239.43 |
Interest Expense | - | - | -1.52 | -0.7 | - | -0.33 |
Interest & Investment Income | - | - | 4.6 | 12.44 | 18.4 | 11.78 |
Earnings From Equity Investments | -3.44 | - | -0.44 | 0.69 | 0.31 | -1.02 |
Currency Exchange Gain (Loss) | - | - | 0.87 | 0.67 | 1.86 | -0.14 |
Other Non Operating Income (Expenses) | -13.09 | -9.24 | -0.25 | -0.21 | -0.15 | -0.16 |
EBT Excluding Unusual Items | -229.35 | -225.88 | 254 | 554.85 | 180.35 | 249.55 |
Gain (Loss) on Sale of Investments | -34.41 | -34.41 | - | - | - | - |
Gain (Loss) on Sale of Assets | 0.08 | 0.06 | -2.55 | -0.9 | -0.73 | -2.19 |
Asset Writedown | -72.29 | -71.67 | -0.78 | - | - | - |
Other Unusual Items | - | - | 4.41 | 2.91 | 18.07 | 14.2 |
Pretax Income | -335.98 | -331.9 | 255.77 | 563.76 | 197.69 | 261.57 |
Income Tax Expense | -68.86 | -69.32 | 23.68 | 62.75 | 16.16 | 18.01 |
Net Income | -267.12 | -262.58 | 232.09 | 501.01 | 181.54 | 243.55 |
Net Income to Common | -267.12 | -262.58 | 232.09 | 501.01 | 181.54 | 243.55 |
Net Income Growth | - | - | -53.67% | 175.98% | -25.46% | -41.77% |
Shares Outstanding (Basic) | 347 | 410 | 414 | 414 | 413 | 393 |
Shares Outstanding (Diluted) | 347 | 410 | 414 | 414 | 413 | 393 |
Shares Change (YoY) | -16.01% | -1.01% | 0.10% | 0.36% | 5.03% | 7.07% |
EPS (Basic) | -0.77 | -0.64 | 0.56 | 1.21 | 0.44 | 0.62 |
EPS (Diluted) | -0.77 | -0.64 | 0.56 | 1.21 | 0.44 | 0.62 |
EPS Growth | - | - | -53.72% | 175.00% | -29.03% | -45.61% |
Free Cash Flow | -90.08 | -175.28 | -135.92 | -215.46 | -250.91 | -492.58 |
Free Cash Flow Per Share | -0.26 | -0.43 | -0.33 | -0.52 | -0.61 | -1.25 |
Dividend Per Share | - | - | 0.169 | 0.150 | 0.150 | 0.100 |
Dividend Growth | - | - | 12.67% | - | 50.00% | - |
Gross Margin | 72.06% | 73.43% | 83.23% | 88.47% | 83.02% | 80.98% |
Operating Margin | -36.06% | -35.80% | 20.40% | 29.70% | 14.93% | 19.92% |
Profit Margin | -45.26% | -43.40% | 18.88% | 27.46% | 16.94% | 20.26% |
Free Cash Flow Margin | -15.27% | -28.97% | -11.06% | -11.81% | -23.42% | -40.98% |
EBITDA | -75.17 | -85.68 | 354.92 | 633.94 | 230.87 | 307.76 |
EBITDA Margin | -12.74% | -14.16% | 28.88% | 34.74% | 21.55% | 25.60% |
D&A For EBITDA | 137.65 | 130.96 | 104.18 | 91.99 | 70.94 | 68.34 |
EBIT | -212.83 | -216.64 | 250.74 | 541.96 | 159.93 | 239.43 |
EBIT Margin | -36.06% | -35.80% | 20.40% | 29.70% | 14.93% | 19.92% |
Effective Tax Rate | - | - | 9.26% | 11.13% | 8.17% | 6.89% |
Revenue as Reported | - | - | 1,229 | 1,825 | 1,071 | 1,202 |
Advertising Expenses | - | - | 435.57 | 568.76 | 371.28 | 411.83 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.